Literature DB >> 12183658

Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat.

Laurent Diop1, Frederic Raymond, Helene Fargeau, Francine Petoux, Maria Chovet, Annette M Doherty.   

Abstract

In human, digestive disorders are often associated with visceral pain. In these pathologies, visceral pain threshold is decreased indicating a visceral hypersensitivity. Pregabalin [CI-1008; S-(+)-3-isobutylgaba] presents antihyperalgesic actions in inflammatory somatic pain models. This study was designed to evaluate 1) the effect of injection of TNBS into the colon on visceral pain threshold, and 2) the antihyperalgesic effect of pregabalin on TNBS-induced chronic colonic allodynia. A significant decrease in the colonic pain threshold was observed in trinitrobenzene sulfonic acid (TNBS)-treated animals (17.8 +/- 1.27 versus 43.4 +/- 1.98 mm Hg). Pregabalin (30-200 mg/kg s.c.) and morphine (0.1-1 mg/kg s.c.) showed a dose-related inhibition of TNBS-induced colonic allodynia. Pregabalin did not inhibit the colonic inflammatory effect of TNBS. In normal conditions (control animals), morphine (0.3 mg/kg s.c.) significantly increased the colonic pain threshold, whereas pregabalin (200 mg/kg s.c.) did not modify the colonic pain threshold. Pregabalin suppressed the TNBS-induced colonic allodynia but did not modify the colonic threshold in normal conditions. The ability of pregabalin to block the chronic colonic allodynia indicates that it is effective in abnormal colonic hypersensitivity, suggesting a possible effect in chronic pain in irritable bowel syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183658     DOI: 10.1124/jpet.302.3.1013

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  29 in total

Review 1.  Targeting voltage-gated sodium channels for treatment for chronic visceral pain.

Authors:  Fei-Hu Qi; You-Lang Zhou; Guang-Yin Xu
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

Review 2.  No quiet surrender: molecular guardians in multiple sclerosis brain.

Authors:  Lawrence Steinman
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

3.  alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?

Authors:  Michael Camilleri
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

4.  Pregabalin decreases visceral pain and prevents spinal neuronal activation in rats.

Authors:  M Million; L Wang; D W Adelson; F Roman; L Diop; Y Taché
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

5.  [Effectiveness and time to onset of pregabalin in patients with neuropathic pain].

Authors:  R Freynhagen; P Busche; C Konrad; M Balkenohl
Journal:  Schmerz       Date:  2006-08       Impact factor: 1.107

6.  Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat.

Authors:  Anthony C Johnson; Beverley Greenwood-Van Meerveld; John McRorie
Journal:  Dig Dis Sci       Date:  2011-05-12       Impact factor: 3.199

Review 7.  The use of non-narcotic pain medication in pediatric gastroenterology.

Authors:  Adrian Miranda; Miguel Saps
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

8.  Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.

Authors:  Johanna Iturrino; Michael Camilleri; Irene Busciglio; Duane Burton; Alan R Zinsmeister
Journal:  Dig Liver Dis       Date:  2013-10-04       Impact factor: 4.088

Review 9.  Visceral analgesics: drugs with a great potential in functional disorders?

Authors:  Sylvie Bradesi; Jeremy Herman; Emeran A Mayer
Journal:  Curr Opin Pharmacol       Date:  2008-09-26       Impact factor: 5.547

10.  Pregabalin suppresses nociceptive behavior and central sensitization in a rat trigeminal neuropathic pain model.

Authors:  Ye Cao; Hua Wang; Chen-Yu Chiang; Jonathan O Dostrovsky; Barry J Sessle
Journal:  J Pain       Date:  2013-02       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.